Genedrive plc (LON: GDR) is the topic of conversation when Dr Dorothea Hill joins DirectorsTalk. After releasing a note anticipating accelerated news flow from Genedrive Dorothea gives us an update as to what has been happening within the company, the kind of updates she is expecting, what investors should understand when evaluating diagnostics, going forward what we should be looking for and company valuation.
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific.
The company has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India. The company also has test in development for tuberculosis (MTB) and Antibiotic Induced Hearing Loss (AIHL).